---
title: "STRO.US (STRO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/STRO.US/news.md"
symbol: "STRO.US"
name: "STRO.US"
parent: "https://longbridge.com/en/quote/STRO.US.md"
datetime: "2026-05-20T10:41:15.281Z"
locales:
  - [en](https://longbridge.com/en/quote/STRO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/STRO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/STRO.US/news.md)
---

# STRO.US (STRO.US) — Related News

### [Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 14% Upside](https://longbridge.com/en/news/286621602.md)
*2026-05-15T22:20:08.000Z*
> Sutro Biopharma, Inc.'s stock price target has been raised to $43.64, indicating a potential upside of 14%. Analysts' es

### [Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts](https://longbridge.com/en/news/286599325.md)
*2026-05-15T17:55:16.000Z*
> Analyst Charles Zhu of LifeSci Capital maintains a Buy rating on Sutro Biopharma with a price target of $54.00, citing s

### [Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside](https://longbridge.com/en/news/286572943.md)
*2026-05-15T13:20:07.000Z*
> Sutro Biopharma, Inc.'s stock price target has been raised from $35.73 to $41.64, indicating an 8% potential upside base

### [Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential](https://longbridge.com/en/news/286482209.md)
*2026-05-14T23:45:18.000Z*
> TD Cowen analyst Tara Bancroft has reiterated a Buy rating on Sutro Biopharma (STRO) due to the promising Phase I readou

### [Sutro Biopharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.52 M](https://longbridge.com/en/news/286463635.md)
*2026-05-14T20:29:34.000Z*
### [This Palantir Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday](https://longbridge.com/en/news/284804624.md)
*2026-04-30T15:49:46.000Z*
> Top analysts have initiated coverage on Sutro Biopharma Inc (NASDAQ:STRO) with an Outperform rating and a price target o

### [Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0%](https://longbridge.com/en/news/284765823.md)
*2026-04-30T12:08:21.000Z*
> Sutro Biopharma, Inc. (NASDAQ:STRO) experienced a 17.0% increase in short interest in April, totaling 748,699 shares as 

### [Sutro Biopharma (NASDAQ:STRO) Shares Gap Down   - What's Next?](https://longbridge.com/en/news/284248592.md)
*2026-04-27T16:23:24.000Z*
> Sutro Biopharma (NASDAQ:STRO) shares gapped down from $34.83 to $33.17 before opening at $33.85. Analysts have mixed rat